BMN673 Is a PARP Inhibitor with Unique Radiosensitizing Properties: Mechanisms and Potential in Radiation Therapy

SIMPLE SUMMARY: PARP inhibitors (PARPi) have broad applicability as monotherapy in tumors with HR defects. However, their combination with radiotherapy (RT) is less advanced owing to the rather modest radiosensitization typically achieved with most tested PARPi, including olaparib. Tumor resistance...

Descripción completa

Detalles Bibliográficos
Autores principales: Soni, Aashish, Lin, Xixi, Mladenov, Emil, Mladenova, Veronika, Stuschke, Martin, Iliakis, George
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9688666/
https://www.ncbi.nlm.nih.gov/pubmed/36428712
http://dx.doi.org/10.3390/cancers14225619

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9688666/
https://www.ncbi.nlm.nih.gov/pubmed/36428712
http://dx.doi.org/10.3390/cancers14225619

Ejemplares similares